Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
  • Alerts
  • Podcasts
  • Subscriptions

Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension

Pierre-Simon Bellaye, Toyoshi Yanagihara, Elise Granton, Seidai Sato, Chiko Shimbori, Chandak Upagupta, Jewel Imani, Nathan Hambly, Kjetil Ask, Jack Gauldie, Marc Iglarz, Martin Kolb
European Respiratory Journal 2018; DOI: 10.1183/13993003.01857-2017
Pierre-Simon Bellaye
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, CanadaCentre George-François Leclerc (CGFL), plateforme d'imagerie et radiothérapie préclinique, Dijon, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toyoshi Yanagihara
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elise Granton
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seidai Sato
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, CanadaDept of Respiratory Medicine and Rheumatology, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chiko Shimbori
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chandak Upagupta
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jewel Imani
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathan Hambly
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kjetil Ask
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Gauldie
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Iglarz
Actelion Pharmaceuticals Ltd. - Allschwil, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Kolb
Firestone Institute for Respiratory Health, Research Institute at St Joseph's Healthcare, Dept of Medicine, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Extract

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with unknown cause. Two drugs, nintedanib and pirfenidone, have been shown to slow, but not stop disease progression. Pulmonary hypertension (PH) is a frequent complication in IPF patients associated with poor prognosis. Macitentan is a dual endothelin receptor antagonist which is approved for PAH treatment. We hypothesised that the treatment of AdTGF-β1-induced pulmonary fibrosis animals with macitentan will result in improvement of PH due to chronic lung disease and limitation of fibrosis progression.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Bellaye has nothing to disclose.

Conflict of interest: Dr. Yanagihara has nothing to disclose.

Conflict of interest: Dr. Granton has nothing to disclose.

Conflict of interest: Dr. Sato has nothing to disclose.

Conflict of interest: Dr. Shimbori has nothing to disclose.

Conflict of interest: Dr. Upagupta has nothing to disclose.

Conflict of interest: Dr. Imani has nothing to disclose.

Conflict of interest: Dr. Hambly has nothing to disclose.

Conflict of interest: Dr. Ask has nothing to disclose.

Conflict of interest: Dr. Gauldie has nothing to disclose.

Conflict of interest: Dr. Iglarz reports other from Actelion Pharmaceuticals Ltd., outside the submitted work; .

Conflict of interest: Dr. Kolb reports grants and personal fees from Roche, grants and personal fees from Boehringer Ingelheim, grants and personal fees from GSK, grants and personal fees from Gilead, grants from Actelion, grants from Respivert, personal fees from Astra Zeneca, grants and personal fees from Prometic, personal fees from Genoa, grants and personal fees from Alkermes, grants from Synairgen, outside the submitted work; .

  • Copyright ©ERS 2018
View Full Text

INDIVIDUALS

Log in using your username and password

– ERS members: log in with your myERS username and password.
– Other users: log in with the credentials you created when you registered.
Forgot your user name or password?
Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

CONTACT US

If you have any questions about the ERS publications website, please contact journals@ersnet.org

Next
Back to top
View this article with LENS
Vol 53 Issue 2 Table of Contents
European Respiratory Journal: 53 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension
Pierre-Simon Bellaye, Toyoshi Yanagihara, Elise Granton, Seidai Sato, Chiko Shimbori, Chandak Upagupta, Jewel Imani, Nathan Hambly, Kjetil Ask, Jack Gauldie, Marc Iglarz, Martin Kolb
European Respiratory Journal Jan 2018, 1701857; DOI: 10.1183/13993003.01857-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension
Pierre-Simon Bellaye, Toyoshi Yanagihara, Elise Granton, Seidai Sato, Chiko Shimbori, Chandak Upagupta, Jewel Imani, Nathan Hambly, Kjetil Ask, Jack Gauldie, Marc Iglarz, Martin Kolb
European Respiratory Journal Jan 2018, 1701857; DOI: 10.1183/13993003.01857-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
  • Info & Metrics
  • PDF

Subjects

  • Pulmonary vascular disease
  • Lung biology and experimental studies
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Exercise intolerance in comorbid COPD-heart failure: the role of impaired aerobic function
  • Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests
  • The Electronic Asthma Management System (eAMS) Improves Primary Care Asthma Management
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Collections
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2019 by the European Respiratory Society